Peter Schmid
Westdeutsche Studiengruppe GmbH · Fliethstraße 112-114 41061 Moenchengladbach Germany · Queen Mary University of London
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Registry trials as an overall official
23
all conditions, ClinicalTrials.gov
NIH grants tied to them
1
7 more share only the name and are not shown
Trial papers in breast cancer
89
PubMed author-name match
Trials
Studies that name Peter Schmid as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:49 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT07281833 · Phase III Study to Evaluate the Safety, Efficacy, and Impact on Quality of Life of Capivasertib Alongside Standard-of-care Endocrine Treatment in Patients With HR+/HER2- Advanced Breast Cancer and Progression on Prior Endocrine-based TreatmentWomen's Cancer Study Group GmbH · recruiting · Breast Cancer, HR-positive Breast Cancer, Advanced Breast Cancer · principal investigator
- Ph3NCT07242352 · Marker - Adjusted Therapy Comparing Adjuvant Elacestrant With Standard Endocrine Treatment in Genomically and/or Clinically High-risk ER+/HER2- eBCWomen's Cancer Study Group GmbH · recruiting · Breast Cancer, HR+/HER2- Breast Cancer · principal investigator
- Ph3NCT07178730 · NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast CancerWomen's Cancer Study Group GmbH · not yet recruiting · Breast Cancer, Triple-negative Breast Cancer · principal investigator
- N/ANCT06978478 · An Imaging Study in ER Negative Breast Cancer by Targeting αvβ6Queen Mary University of London · withdrawn · Breast Cancer · principal investigator
- Ph2NCT06954480 · Investigating Datopotamab Deruxtecan Plus Durvalumab Versus Datopotamab Deruxtecan in Patients With PDL1-negative Metastatic Triple-negative Breast CancerQueen Mary University of London · recruiting · Triple Negative Breast Cancer · study director
- Ph3NCT06081244 · NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III)Women's Cancer Study Group GmbH · recruiting · Triple Negative Breast Cancer · principal investigator
- Early Ph1NCT05960266 · Immunological Analysis of Lymph Node Tissue After Intralymphatic Immunotherapy: A Prospective Case Control StudyUniversity of Zurich · completed · Hypersensitivity, Hay Fever, Rhinitis, Allergic, Seasonal · principal investigator
- Ph2NCT05498896 · Investigate the Contribution of Ipatasertib to Neoadjuvant Chemotherapy Plus Atezolizumab in TNBCQueen Mary University of London · active not recruiting · Triple Negative Breast Cancer · study chair
- Ph2/Ph3NCT05378698 · Effects of Tralokinumab in the Skin: an Immunologic and Molecular InvestigationUniversity of Zurich · terminated · Atopic Dermatitis · principal investigator
- N/ANCT04285996 · IMaging Pilot Study of the αvβ6 Integrin Radiotracer [18F]-A20FMDV2 in PAtients With Solid Cancer TypesQueen Mary University of London · completed · Cancer · principal investigator
- N/ANCT04239131 · Prospective Study About Sensitization Pattern to Insects as Food Source in Patients With House Dust Mite AllergyUniversity of Zurich · completed · Hypersensitivity, Food · principal investigator
- Ph3NCT03997123 · Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBCAstraZeneca · active not recruiting · Triple Negative Breast Neoplasms · principal investigator
- Ph2NCT03841747 · Paclitaxel Plus Pembrolizumab vs. Paclitaxel Weekly in ER+ Luminal B Metastatic Breast CancerQueen Mary University of London · withdrawn · Breast Cancer · principal investigator
- Ph1/Ph2NCT03742102 · A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast CancerAstraZeneca · active not recruiting · Triple Negative Breast Neoplasms · principal investigator
- Ph2NCT03620643 · Crizotinib in Lobular Breast, Diffuse Gastric and Triple Negative Lobular Breast Cancer or CDH1-mutated Solid TumoursRoyal Marsden NHS Foundation Trust · completed · Lobular Breast Carcinoma, Gastric Cancer, Triple Negative Breast Cancer · study chair
- Ph2NCT03395899 · Pre-operative Immunotherapy Combination Strategies in Breast CancerQueen Mary University of London · completed · Breast Cancer, Estrogen Receptor-positive Breast Cancer · principal investigator
- Ph2NCT02676986 · Short-term Preoperative Treatment With Enzalutamide, Alone or in Combination With Exemestane in Primary Breast CancerQueen Mary University of London · completed · Primary Breast Cancer ER+ve, Primary Breast Cancer AR+ve TNBN · principal investigator
- Ph1/Ph2NCT02583542 · A Study of AZD2014 in Combination With Selumetinib in Patients With Advanced CancersQueen Mary University of London · unknown · Triple-Negative Breast Cancer, Squamous Cell Lung Cancer, Non-squamous Cell Lung Cancer With KRAS Mutations · study director
- Ph2NCT02423590 · Study of Gemcitabine/Carboplatin First-line Chemotherapy +/- Apatorsen in Advanced Squamous Cell Lung CancersQueen Mary University of London · unknown · Squamous Cell Lung Cancer · study chair
- Ph2NCT02423603 · PAKT: AZD5363 in Combination With Paclitaxel in Triple-Negative Advanced or Metastatic Breast CancerQueen Mary University of London · completed · Metastatic Breast Cancer · study chair
- Ph2NCT02216786 · A Randomized Study of AZD2014 in Combination With Fulvestrant in Metastatic or Advanced Breast CancerQueen Mary University of London · completed · Estrogen Receptor Positive Breast Cancer · principal investigator
- Ph2NCT01635127 · Efficacy Study of Canakinumab to Treat UrticariaUniversity of Zurich · unknown · Chronic Idiopathic Urticaria · principal investigator
- Ph3NCT00464373 · Botulinum Toxin Type A for the Treatment of Male Chronic Pelvic Pain SyndromeDaniel Stephan Engeler · terminated · Chronic Prostatitis With Chronic Pelvic Pain Syndrome, Prostatitis · study director
Grants
NIH projects from RePORTER, fetched 2026-11-12 10:49 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 7 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- RhoFED CDSMCU01AI178773 · NIAID · RHO FEDERAL SYSTEMS DIVISION, INC. · fiscal years 2023 to 2024 · $444,465 awarded in 2024Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name in breast cancer, ranked by citations from NIH iCite, fetched 2026-11-12 10:49 UTC. The ranking covers the 200 most relevant of 89 PubMed records, and a shared surname and initials can bring in a namesake. All 89 on PubMed
- Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.N Engl J Med · 20183,478 citationsRCR 124.7
- Pembrolizumab for Early Triple-Negative Breast Cancer.N Engl J Med · 20202,673 citationsRCR 117.0
- 2,392 citationsRCR 180.8
- 1,567 citationsRCR 65.6
- Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer.N Engl J Med · 20211,463 citationsRCR 83.1
- 1,071 citationsRCR 71.6
- Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer.N Engl J Med · 20221,056 citationsRCR 72.2
- 998 citationsRCR 41.2
- Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study.Ann Oncol · 2019696 citationsRCR 24.2
- Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer: A Phase 1 Study.JAMA Oncol · 2019654 citationsRCR 23.2